Equillium Announces Presentation at the 6th Annual Dermatology Drug Development Summit
03 November 2022 - 11:00PM
Business Wire
Preclinical and translational data supports
EQ101 for the treatment of alopecia areata
Multi-Cytokine Inhibitors may provide a more
selective and potent approach to treatment than direct JAK
inhibition
A phase 2 study of EQ101 in patients with
alopecia areata to be initiated in Q4 2022
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology
company focused on developing novel therapeutics to treat severe
autoimmune and inflammatory disorders with high unmet medical need,
today announced a presentation at the 6th Annual Dermatology Drug
Development Summit. The presentation highlights Equillium’s
Multi-Cytokine Inhibitor EQ101 as a novel molecular compound to
treat alopecia areata. Data on the first-in-class tri-specific
inhibitor, targeting Il-2, IL-9 and IL-15, were presented by Dr.
Stephen Connelly, co-founder and chief scientific officer of
Equillium. The Summit is taking place at the Boston Park Plaza
November 1-3.
“Responsible for the signaling of more than 50 cytokines, the
JAK/STAT pathways have become key targets for drug development,
with multiple JAK inhibitors approved over the last decade. The
problem, however, is that only a handful of these cytokines
contribute to disease pathology, while the rest are physiologically
important, thus leading to treatment emergent toxicities and
long-term safety concerns by regulators,” said Dr. Connelly. “EQ101
is a first-in-class, tri-specific cytokine inhibitor selectively
targeting IL-2, IL-9 and IL-15 at the receptor level that may
afford significant advantages over other approaches, including JAK
inhibition. These cytokines have shown to be important in multiple
dermatological diseases and with EQ101 previously achieving
favorable safety profile and clinical validation in treating
cutaneous T cell lymphoma patients, we look forward to initiating a
Phase 2 clinical study in subjects with alopecia areata, very
soon.”
The presentation, titled “EQ101: A Multi-specific Cytokine
Inhibitor to treat Alopecia Areata”, focuses on how the
Multi-Cytokine Inhibitor (MCi) platform has been used to target the
common gamma receptor to generate EQ101. First-in-human studies of
EQ101 were safe and well tolerated while a previous Phase 1/2
Proof-of-Concept study in cutaneous T cell lymphoma (CTCL)
demonstrated clinically meaningful improvement in skin scores.
EQ101 was also shown to be more effective than ruxolitinib at hair
regrowth and suppression of cytotoxic CD8+ T-cells in a model of
immune-mediated hair loss. The differentiated approach of EQ101 to
block multiple cytokines at the receptor level may provide a more
selective and potent approach to treatment than direct JAK
inhibition and may position the molecule well as an alternative or
substitution to JAK inhibitors.
The presentation is available on the Multi-Cytokine tab of the
Presentations page under the Technology section of the company
website.
About Multi-Cytokine Platform: EQ101 & EQ102
Our proprietary Multi-Cytokine Platform (MCP) generates
rationally designed composite peptides that selectively block key
cytokines at the shared receptor level targeting pathogenic
cytokine redundancies and synergies while preserving non-pathogenic
signaling. This approach provides multi-cytokine inhibition at the
receptor level and is expected to avoid the broad
immuno-suppression and off-target safety liabilities that may be
associated with other therapeutic classes, such as JAK inhibitors.
Many immune-mediated diseases are driven by the same combination of
dysregulated cytokines, and we believe identifying the key
cytokines for these diseases will allow us to target and develop
customized treatment strategies for multiple autoimmune and
inflammatory diseases.
Current MCP assets include EQ101, a first-in-class, selective,
tri-specific inhibitor of IL-2, IL-9 and IL-15, and EQ102, a
first-in-class, selective, bi-specific inhibitor of IL-15 and
IL-21.
About Equillium
Equillium is a clinical-stage biotechnology company leveraging a
deep understanding of immunobiology to develop novel therapeutics
to treat severe autoimmune and inflammatory disorders with high
unmet medical need. The company’s pipeline consists of the
following novel immunomodulatory assets targeting
immuno-inflammatory pathways. Itolizumab, a first-in-class
monoclonal antibody that targets the CD6-ALCAM signaling pathway
which plays a central role in the modulation of effector T cells,
is currently in a Phase 3 study for patients with acute
graft-versus-host disease (aGVHD) and is in a Phase 1b study for
patients with lupus/lupus nephritis. EQ101 is a first-in-class
tri-specific cytokine inhibitor that selectively targets IL-2,
IL-9, and IL-15. Equillium expects to begin enrolling patients in
an alopecia areata Phase 2 study of EQ101 in the fourth quarter of
2022. EQ102 is a bi-specific cytokine inhibitor that selectively
targets IL-15 and IL-21. Equillium is currently enrolling patients
in a Phase 1 study of EQ102, including healthy volunteers and
celiac disease patients.
For more information, visit www.equilliumbio.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", “could”, “continue”,
"expect", "estimate", “may”, "plan", "outlook", “future” and
"project" and other similar expressions that predict or indicate
future events or trends or that are not statements of historical
matters. Because such statements are subject to risks and
uncertainties, many of which are outside of the Company’s control,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such statements
include, but are not limited to statements regarding the potential
benefits of using our multi-cytokine platform to develop treatments
for patients with certain autoimmune and inflammatory diseases,
Equillium’s plans and expected timing for developing EQ101 and
EQ102 including the expected timing of initiating, completing and
announcing further results from Phase 2 and Phase 1 studies,
respectively, the potential for any of Equillium’s ongoing or
planned clinical studies to show safety or efficacy, Equillium’s
anticipated timing of regulatory review and feedback, and
Equillium’s plans and expected timing for developing its product
candidates and potential benefits of its product candidates. Risks
that contribute to the uncertain nature of the forward-looking
statements include: uncertainties related to the abilities of the
leadership team to perform as expected; Equillium’s ability to
execute its plans and strategies; risks related to performing
clinical studies; the risk that interim results of a clinical study
do not necessarily predict final results and that one or more of
the clinical outcomes may materially change as patient enrollment
continues, following more comprehensive reviews of the data, and as
more patient data become available; potential delays in the
commencement, enrollment and completion of clinical studies and the
reporting of data therefrom; the risk that studies will not be
completed as planned; Equillium’s plans and product development,
including the initiation and completion of clinical studies and the
reporting of data therefrom; whether the results from clinical
studies will validate and support the safety and efficacy of
Equillium’s product candidates; changes in the competitive
landscape; uncertainties related to Equillium’s capital
requirements; and having to use cash in ways or on timing other
than expected and the impact of market volatility on cash reserves.
These and other risks and uncertainties are described more fully
under the caption "Risk Factors" and elsewhere in Equillium's
filings and reports, which may be accessed for free by visiting
EDGAR on the SEC web site at http://www.sec.gov and on the
Company’s website under the heading “Investors.” Investors should
take such risks into account and should not rely on forward-looking
statements when making investment decisions. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Equillium undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221103005508/en/
Michael Moore Vice President, Investor Relations & Corporate
Communications 619-302-4431 ir@equilliumbio.com
Equillium (NASDAQ:EQ)
Historical Stock Chart
From Apr 2024 to May 2024
Equillium (NASDAQ:EQ)
Historical Stock Chart
From May 2023 to May 2024